Slow-wave sleep modulation and stress-induced insomnia in EEG models
Sleep enhancement peptide research focuses primarily on DSIP (Delta Sleep-Inducing Peptide), a nonapeptide originally isolated from rabbit venous blood during natural sleep, and Selank, which has secondary anxiolytic-mediated sleep-improving effects. DSIP was discovered by Schoenenberger and colleagues in 1977 and characterised by its ability to increase the proportion of slow-wave (delta) sleep in multiple species. Research models include polysomnographic recording in freely moving rodents, stress-induced insomnia models, and neonatal/aged animal sleep architecture studies.
DSIP interacts with opioid receptors (µ and δ) and modulates GABA-B receptor activity, collectively shifting sleep architecture toward slow-wave dominance. It also suppresses corticotropin-releasing hormone (CRH) release, providing indirect stress-axis modulation that may contribute to sleep onset facilitation. Selank's sleep benefits are mediated through its GABAergic and anxiolytic mechanisms — reducing the hyperarousal that characterises stress-induced insomnia without the respiratory depression associated with benzodiazepines.
| Protocolo | Peptídeos | Duração | Dosagem | Ponto final |
|---|---|---|---|---|
| Polysomnography Model (DSIP) | DSIP | Acute (single dose) to 5-day chronic | 25–200 µg/kg · Acute: single IV bolus; chronic: once daily IV | EEG delta power (0.5–4 Hz band), NREM/REM ratio, sleep latency (time to first NREM epoch), total sleep time |
| Stress-Induced Insomnia Model (Selank) | Selank | 7 days | 100–300 µg per animal · Once daily intranasal, 60 min before lights-off | Sleep onset latency (EEG), serum corticosterone (evening sample), NREM delta power, open-field locomotion (to control for sedation) |
Intravenous injection of DSIP extracted from sleeping rabbit blood into alert rabbits produced a significant and reproducible increase in delta wave activity and facilitated transition to NREM sleep within 30 minutes.
PMID 409316✓Prós
- DSIP improves sleep architecture (specifically slow-wave sleep) rather than simply increasing total sedation
- No respiratory depression — critical safety advantage over conventional sleep medications
- Selank shows no withdrawal or dependence effects in published rodent studies — unlike benzodiazepines
- Selank is intranasal — no injections required
- Cortisol-reducing effect of Selank may have positive downstream effects beyond sleep
- Non-addictive mechanism — neither compound acts on GABA-A receptors the way benzodiazepines do
×Contras
- DSIP has an extremely short plasma half-life (~30 minutes) — the compound degrades quickly, making dosing protocols challenging
- DSIP is practically unavailable from EU vendors as of 2026 — specialised custom synthesis required
- Human clinical data for DSIP is very limited and inconsistent across published studies
- Selank's sleep benefits are a secondary effect of its anxiolytic action — it is not a direct sleep-inducing agent
- Effects of DSIP in human volunteers have shown high inter-individual variability in the few published trials
- Without access to sleep EEG monitoring, it is difficult to verify sleep architecture improvement objectively
Does DSIP induce sleep immediately, like a sedative?
No. DSIP modulates sleep architecture by increasing slow-wave (delta) sleep proportion rather than inducing acute sedation. It reduces sleep latency and shifts sleep pressure toward NREM, but does not produce the sedation or anxiolysis associated with benzodiazepines or barbiturates.
Why is DSIP difficult to source from EU vendors?
DSIP is a relatively low-demand research peptide with a very short plasma half-life that makes in vivo studies technically demanding. Few EU vendors stock it routinely; researchers typically order from specialised synthesis laboratories on a custom basis.
Mais desta região.
Outros artigos que cobrem os fornecedores, marco regulatório e peptídeos de pesquisa desta região.